Abstract: The present invention provides a vascular treatment material which has high safety, and also can exert high organization acceleration effect. The present invention also provides a commercially available vascular treatment material, which is easy to produce and can be easily sterilized, and also can be stored for a long period. Disclosed is a vascular treatment material including a coil on which statin is loaded. It is preferred that a wire forming the coil is made of at least one kind of metal selected from platinum, tungsten, gold, cobalt, chromium, titanium, niobium, aluminum, tantalum, iron, nickel and the like. The vascular treatment material of the present invention is particularly useful, which is placed in a blood vessel for embolization treatment, or which accelerates organization for prevention of recanalization of aneurysm or for prevention of rupture of aneurysm.

Abstract: A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.

Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.

Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.

Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.

Abstract: A stent having a generally tubular body formed of ring units formed of a plurality of cells each and expandable in the radial direction, wherein each ring unit is constituted of cells connected to one another above and below, arranged to surround the center line of the stent, the ring units are arranged in the axial direction of the stent, and are connected with connector portions, each connector portion is formed of curved portions each having an arch and a generally linear portion continued thereto, 3 to 8 cells are arranged in the axial direction per 10 mm of the length of the stent, and the ratio of the length of the cell in the axial direction and the length of the connector portion is determined such that on the basis that when the length of the cell is 100, that of the connector portion 50 to 100, thereby securing flexibility and radial sustaining force.

Abstract: A conductive substrate for introducing a nucleic acid into a cell, which comprises a carbon nanotube with a carboxyl group, and a nucleic acid, the carbon nanotube and the nucleic acid being loaded on an electrode substrate with a cationic surface.

Abstract: The present invention relates to a method of introducing nucleic acids into cells by electroporation, comprising the step (A) of loading nucleic acids to the surface of an electrode; the step (B) of adhering cells on the obtained nucleic acid-loaded electrode surface; and the step (C) of applying electric pulses to the adhering cells. According to this method, not only efficient introduction of a gene into cells but also gene introduction at desirable timing and at desirable sites can be performed without damaging the adhering cells.

Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.

Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.

Abstract: A surface plasmon sensor includes a light guide reflection plate, a surface plasmon resonance layer formed on a first surface of the light guide reflection plate, a light emitting unit having a light source disposed on an end surface of the light guide reflection plate, and a light receiving element. The surface plasmon resonance layer includes a metal layer. The light guide reflection plate includes at least one first reflection surface inclined against the first surface. The light guide reflection plate is configured to transmit light emitted by the light source. The at least one first reflection surface is configured reflect the light to the surface plasmon resonance layer. The metal layer is configured to reflect the light reflected by the at least one first reflection surface. The light receiving element is configured to receive the light reflected by the metal layer.

Abstract: An Object of the present invention is to provide a process for producing a nerve cell by inducing differentiation of an embryonic stem cell, a method for inducing differentiation of the embryonic stem cell into a nerve cell, a medium to be used in the production process or differentiation induction method, or a method for improving purity of the nerve cell obtained by inducing differentiation of the embryonic stem cell. The present invention provides a process for producing a nerve cell which is applicable to treatment of neurodegenerative disease or the like easily, selectively or inexpensively by inducing differentiation induction of an embryonic stem cell using vitamin B12 or a salt thereof and heparin, a substance having heparin-like activity or a salt.

Abstract: A method for obtaining a solution having activity to induce differentiation of an embryonic stem cell into an ectodermal cell or ectoderm-derived cell, which comprises culturing a stromal cell in a culture comprising a polyanionic compound and recovering the culture; a solution having activity to induce differentiation of an embryonic stem cell into an ectodermal cell or ectoderm-derived cell, which is obtainable by the method; and an agent for inducing differentiation of an embryonic stem cell into an ectodermal cell or ectoderm-derived cell.

Abstract: A surface plasmon sensor includes a light guide reflection plate, a surface plasmon resonance layer formed on a first surface of the light guide reflection plate, a light emitting unit having a light source disposed on an end surface of the light guide reflection plate, and a light receiving element. The surface plasmon resonance layer includes a metal layer. The light guide reflection plate includes at least one first reflection surface inclined against the first surface. The light guide reflection plate is configured to transmit light emitted by the light source. The at least one first reflection surface is configured reflect the light to the surface plasmon resonance layer. The metal layer is configured to reflect the light reflected by the at least one first reflection surface. The light receiving element is configured to receive the light reflected by the metal layer.

Abstract: The present invention relates to a method of introducing nucleic acids into cells by electroporation, comprising the step (A) of loading nucleic acids to the surface of an electrode; the step (B) of adhering cells on the obtained nucleic acid-loaded electrode surface; and the step (C) of applying electric pulses to the adhering cells. According to this method, not only efficient introduction of a gene into cells but also gene introduction at desirable timing and at desirable sites can be performed without damaging the adhering cells.

Abstract: A stent (1) formed into a generally or substantially tubular body and expandable radially outward from inside of the tubular body, wherein cells (6) are connected vertically and so arranged as to surround the central axis (C1) of the stent (1) and thereby to form annular units (4), the annular units (4) are extended along the axis of the stent (1), adjacent annular units (4) are connected at least at one portion by a connecting part (5), each of the cells (6) has at least one bent portion, and the angle of the bent portion after expansion of the tubular body until the diameter becomes 2.5 mm is larger than 30°. The stent ensures a high flexibility and radial support force, enhances the blood vessel expandability, and suppresses the foreshortening phenomenon and the flare phenomenon.

Abstract: A method for obtaining a solution having activity to induce differentiation of an embryonic stem cell into an ectodermal cell or ectoderm-derived cell, which comprises culturing a stromal cell in a culture comprising a polyanionic compound and recovering the culture; a solution having activity to induce differentiation of an embryonic stem cell into an ectodermal cell or ectoderm-derived cell, which is obtainable by the method; and an agent for inducing differentiation of an embryonic stem cell into an ectodermal cell or ectoderm-derived cell.

Abstract: An embolization device which is placed at a definite position in a vessel cavity in vivo to embolize the vessel cavity. More specifically speaking, an embolization device to be used for plugging a blood vessel or a aneurysm formed in a blood vessel. After being placed in a vessel cavity in vivo, this embolization device promotes not only thrombosis but also organization over the surrounding area, thereby exerting an excellent embolization effect on the vessel cavity. Namely, an embolization device for plugging a vessel cavity in vivo characterized by having biological response modifiers (BRM) which can promote organization and exert an enhanced embolization effect after being placed in a vessel cavity in vivo.

Abstract: The present invention provides a stent for intracranial vascular therapy which can be safely held in the intracranial arteries, induces no biological reaction in the blood vessels due to galvanic corrosion or the like, and has elevated visibility under X-ray radioscopy. A stent of the present invention includes a plurality of main struts and a plurality of link struts as its constituents, wherein the stent is made of a single material having higher radiopacity than that of stainless steel, and the main struts and the link struts each have a width ranging from 100 ?m to 200 ?m and a thickness ranging from 50 ?m to 100 ?m.

Abstract: A stent (1) having a generally tubular body formed of ring units formed of a plurality of cells each and being expandable in the radius direction thereof from inside, wherein each ring unit (4) is constituted of the plurality of cells (6) connected to one another above and below and arranged so as to surround the center line (C1) of the stent forming said tubular body, the ring units are arranged in the axial direction of the stent, ring units are connected through at least one site with connector portions (5), each connector portion is formed of curved portions (8) having at least 2 arches and a generally linear portion (7) continued thereto and therefrom, 3 to 8 cells are arranged in the axial direction of the stent per 10 mm of the length of the stent, and the ratio of the length (6L) of the cell in the axial direction of the stent and the length (5L) of the connector portion in the axial direction of the stent is determined such that on the basis that when the length of the cell in the axial direction of